Sabra Healthcare REIT, Inc. (SBRA) stock slides, “Hold” rating reaffirmed by Jefferies Group LLC Analysts

Sabra Healthcare REIT, Inc. (NASDAQ: SBRA) shares fell on Tuesday January 31 on lower trade volume than normal after a number of analysts weighed in on the investing value of the stock and reiterated thier respective ratings.

Meanwhile, The Dow Jones Industrial Average DJIA, -0.60% fell 140 points, or 0.7%, to 19,833, with 26 of the 30 blue-chip companies trading lower. Nike, Inc. NKE, -1.10% down 2.4% and Intel Corp. INTC, -1.70% off 1%, were leading losses.

The S&P 500 SPX, -0.33% was off by 10 points, or 0.5%, to 2,270 with seven of the 11 main sectors trading lower. Industrials, consumer-discretionary, and technology shares were the worst performers, while real estate and utilities stocks attracted buyers.

The health-care sector, which was down in early trade, rebounded after President Trump called for scaling back drugmaker’s regulation, lowering taxes and prices of medicines.

The Nasdaq Composite COMP, -0.25% declined 31 points, or 0.6%, to 5,581.

Sabra Healthcare REIT, Inc. (NASDAQ: SBRA) had its Hold rating reiterated by equities researchers at Jefferies Group LLC in a research note to investors. With a rating of Hold on the shares, the company has a 52-week high of $26.60. As a means of comparison, a number of other analysts have commented on the stock recently, and the company has secured a consensus one-year price target of $24.33, lower than the opening price of $25.40. Stock prices often shift to the upside on recommendations and new price targets of professional brokerage firms.

Shares of Sabra Healthcare REIT, Inc. (NASDAQ: SBRA) opened at $25.40 yesterday and traded in a range between, $25.39 and $25.54, and last traded at $25.39, a decrease of $0.08 compared to the previous closing price.

Sabra Healthcare REIT, Inc. (NASDAQ: SBRA) currently has a market cap of 1.66B.

Sabra Healthcare REIT, Inc. (NASDAQ: SBRA) Average Daily Trading Volume

28,344 shares crossed the trading desk yesterday, 54 percent lower than the average, out of a total float 63,693,000. lower than normal. Look for trading volume to pick up in the coming days as swing traders often use upticks in trading volume to identify heavy volume accumulation or distribution by institutional investors.

As with all potential breakouts, investors look for volume to be at least 40%-50% higher than normal on the breakout to show that fund managers and other professional investors are jumping in.

Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.

These instituitional investors have teams of analysts researching thousands of stocks. Thus, watching their interests is a good way to make sure you are buying the right stocks.

Sabra Healthcare REIT, Inc. (NASDAQ: SBRA) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By tracking the activity of these professional investors—and the moving averages they affect—it allows for traders to make more effective decisions on trades.

With that in mind, Sabra Healthcare REIT, Inc. (NASDAQ: SBRA) now has a 50-day MA of $24.77 and 200-day MA of $23.90. It has traded in a 52-week range between $14.92 – 26.60 and today’s last price is 4.55%% lower than the 52 week high of $26.60.

Earnings growth is a critical factor to look at when buying stocks and investors look for companies that have increased their earnings by at least 25% for a 3 year period.

DISCLOSURE: The views and opinions expressed in this article do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *